Form 4: Bioxytran CEO David Platt Reports Significant Share Transactions

Bioxytran CEO David Platt reports a series of transactions involving common and preferred stock, including acquisitions, disposals, and conversions, impacting his beneficial ownership.

Summary

• On August 15, 2024, David Platt acquired 1,592,921 shares of common stock at $0.124 per share.
• On August 19, 2024, there were multiple transactions involving common and preferred stock, including exchanges and conversions.
• Insiders exchanged common stock for convertible preferred stock at a 5:1 ratio.
• Shares were acquired through the conversion of debt issued under Rule 3(a)(9).
• The reported transactions involve both direct and indirect ownership, including holdings by NDPD Pharma, Inc. and Naomi Platt.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transactions may influence investor perception of Bioxytran's stock.
• Changes in insider ownership can be a signal to the market.

Key Dates

Keywords

Bioxytran, BIXT, David Platt, Form 4, Beneficial Ownership, Stock Transactions, Convertible Preferred Stock, Common Stock, NDPD Pharma, Naomi Platt